AHMET ŞAHİN

Dr. AHMET ŞAHİN

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2016 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
ZKZehra Karacaer
Zehra Karacaer
BCBanu Cakir
Banu Cakir
HEHakan Erdem
Hakan Erdem
KUKenan Ugurlu
Kenan Ugurlu
GDGul Durmus
Gul Durmus
NONecati Ormeci
Necati Ormeci
The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.

1 January 2023 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
AŞAHMET ŞAHİN
AHMET ŞAHİN
SBSinem Bayrakçı
Sinem Bayrakçı
SASelda Aslan
Selda Aslan
The aim of this study was to investigate the ratios of lactate/albumin, procalcitonin/albumin, and blood urea nitrogen/albumin to predict 14- and 28-day mortality in uroseptic patients. Urosepsis is a disease with high mortality, and early diagnosis and treatment are important.

1 January 2022 in SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital
Verified
Journal Article
Open access
SBSezgin Barutcu
Sezgin Barutcu
AYAbdullah Emre Yildirim
Abdullah Emre Yildirim
AŞAHMET ŞAHİN
AHMET ŞAHİN
MGMurat Taner Gulsen
Murat Taner Gulsen
Objectives:The aim of this study was to evaluate the most ideal inflammatory markers for treatment response and to determine a cutoff value that could predict response to treatment for culture negative neutrocytic ascite (CNNA) patients. Methods: This is a retrospective cross-sectional case-controlled study. Patients with CNNA were evaluated by taking ascites fluid sampling at the beginning and on the 5th day of treatment. Neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and neutrophil-to-monocyte ratio were calculated. Results: Of the 123 cases with cirrhotic ascites disease, 59 were CCNA and 64 were the control group without ascite-fluid infection. There were statistically significant differences for blood monocyte count, NLR (p<0.01), LMR, and C-reactive protein (CRP) (p<0.001) between two groups. Patients in the CNNA group were compared before and after treatment among themselves for the treatment response. There was statistically significant difference in mean platelet volume, monocyte, LMR, and CRP (p<0.05) between two groups. After receiver operator characteristics curve analysis, the best cutoff value for monocyte was <0.64 x 10(3)/mu L (sensitivity 49.2%, specificity 74.6%, positive predictive value [PPV] 65.9%, and negative predictive value [NPV] 59.5%) (p= 1.7 (sensitivity 76.3%, specificity 78%, PPV 77.6%, and NPV 76.7%), and for CRP was 18 mg/L (sensitivity 91.5% specificity 57.6%, PPV 68.4%, and NPV 87.2%) (p<0.001). When LMR and CRP were used together, sensitivity (86.5%), specificity (83.1%), PPV (83.6%), and NPV (86%) were found to be statistically significantly higher (p<0.001). Conclusion: Our results showed that in cirrhotic patients with CNNA, combined LMR + CRP can be used as a novel, low cost and non-invasive test to predict treatment response.

1 September 2023 in Annals of Saudi Medicine
Verified
Journal Article
Open access
AŞAHMET ŞAHİN
AHMET ŞAHİN
OAOzlem Akay
Ozlem Akay
BACKGROUND: Hepatitis C virus (HCV) can cause chronic liver disease, hepatic cirrhosis, hepatocellular carcinoma, liver transplantation, and death. Early diagnosis and treatment are thus vital.OBJECTIVES: We aimed to investigate the sustained virological response (SVR) rates in chronic hepatitis C patients infected with different genotypes, receiving different direct-acting antiviral treatments (DAAs).DESIGN: Retrospective, observationalSETTING: Clinic for infectious diseases and clinical microbiologyPATIENTS AND METHODS: Patients diagnosed with chronic hepatitis C who applied to our outpatient clinic between January 2016 and November 2022 and were treated with a DAA were included in the study. Treatment responses were evaluated after each patient was treated with either ledipasvir plus sofosbuvir (LDV/SOF), LDV/SOF + ribavirin (RBV), SOF+RBV, ombitasvir/paritaprevir/ritonavir plus dasabuvir (OBV/PTV/r +/- DSV) +/- RBV, or glecaprevir plus pibrentasvir (GLE/ PIB). MAIN OUTCOME MEASURES: Sustained virological response (SVR) rates at 12 weeks (SVR12) post-treatment.SAMPLE SIZE: 360 patients. RESULTS: Of 360 patients who met the inclusion criteria, 218 (60.6%) were male and 142 (39.4%) were female with no statistically significant differences in SVR between sexes (P=.252). Nearly all had a SVR (n=353, 98.1%). The median (IQR) age of the patients was 56 (30.3) years. There were 42 (11.7%), 199 (55.3%), 4 (1.1%), 106 (29.4%), 8 (2.2%) and 1 (0.3%) patient with genotypes 1a, 1b, 2, 3, 4 and 5, respectively, and SVR12 did not differ significantly between genotypes (P=.066). SVR12 response was higher in 246 (68.3%) non-injecting drug users compared to 114 (31.7%) injecting drug users (P=.005). The SVR12 response was achieved in 100% of patients with genotypes 1a, 2, 4, and 5. SVR12 response could not be obtained in 1 of 199 genotype 1b patients and 6 of 106 genotype 3 patients. The common feature of 6 reinfection patients with genotype 3 was that they were using intravenous drugs. These 6 patients were reinfected due to their continued intravenous drug use.CONCLUSION: In conclusion, DAAs provide high SVR12 rates in cirrhotic/non-cirrhotic, pegylated interferon-naive/experienced patient groups and in patients infected with all genotypes. DAAs have a high SVR12 rate in patients with chronic hepatitis C.LIMITATIONS: Retrospective, single-center.

7 June 2021 in Turkish Journal of Parasitology
Verified
Journal Article
Closed access
KÖKoray Öncel
Koray Öncel
AŞAHMET ŞAHİN
AHMET ŞAHİN
FEFatih Esmer
Fatih Esmer
In a 2017 data of World Health Organisation, malaria is still an important medical health care problem by threatening 217 million people and causing 435 thousand deaths. In our country, as a result of successful eradication programmes, any domestic cases were not encountered; however, approximately 200 import cases were seen each year from 2013 to 2017. This study aimed to create awareness for cases caused by P. falciparum that are increasingly seen in rare import cases, which displays more severe clinical course than other Plasmodium species.

27 June 2025 in Medicine
Verified
Journal Article
Open access
SBSinem Bayrakçi
Sinem Bayrakçi
AŞAHMET ŞAHİN
AHMET ŞAHİN
OBOnur Bayrakçi
Onur Bayrakçi
SASelda Aslan
Selda Aslan
Ventilator-associated pneumonia (VAP) is one of the most common and serious infections in hospitalized patients. VAP is associated with worse outcomes and significant morbidity and mortality worldwide. Our primary goal in this study was to identify the VAP pathogen with its distribution characteristics, clarify risk factors, prognosis, and outcomes, and help reduce associated morbidity and mortality. This retrospective observational study was conducted between June 2019 and June 2022 in 3 general intensive care units of a training and research hospital. Data on demographic, clinical and laboratory parameters were collected retrospectively from medical cards and electronic records. A total of 204 patients were diagnosed with VAP caused by Gram-negative microorganisms. Chronic renal failure (RF) and neurological diseases were significantly associated with mortality (P = .01, P = .023). The duration of mechanical ventilation before VAP and the duration of mechanical ventilation were significantly longer in survivors compared to non-survivors. The number of patients with early VAP was significantly higher, and the days of VAP were shorter in the non-survivors compared to the survivors (P = .006, P = .016). The number of VAP episodes (P = .0001), the presence of RF, acute respiratory distress syndrome, bacteremia, and sepsis before VAP (<48 hours) were associated with mortality. Intensive care unit and the length of hospital stay were significantly shorter in non-survivors than in survivors (P = .0003, P = .0001). Administration of monotherapy, inadequate empirical antibiotic therapy, inadequate antibiotic therapy (P = .004, P = .002, and P = .0006), persistence of the pathogen (P = .0001), C-reactive protein and procalcitonin levels (P = .002, P = .041) were associated with mortality. The presence of neurological diseases and RF was associated with a greater likelihood of mortality in patients with VAP. As risk factors, early-onset VAP, presence of RF–acute respiratory distress syndrome–bacteremia–sepsis 48 hours before VAP, organ failure, need for hemodialysis, shock and the persistence of the pathogen increased the risk of mortality.